Science

It's an approved diagnostic and therapeutic hormone with a specific, narrow clinical use. The way it's actually used in this market looks nothing like that.

It's part of the human body's own innate immune defense. Whether more of it, applied externally, actually improves wound healing is still an open research question.

The original mouse study produced some of the more striking before-and-after images in aging research. Human data has not followed at anything like the same pace.

Both sound like a seller admitting a problem. They mean very different things about who found the issue and why.

We've covered what happens to buyers when a supplier goes dark. Less examined: where the product itself actually goes.

Some sellers provide one, most don't ask to be checked for one, and almost nobody outside a lab setting reads it. Here's what it's actually for.

It's marketed as an improved, more stable version of BPC-157. The modification is real chemistry — the comparative human evidence for the claimed improvement isn't there yet.

It targets a different hormone pathway than the GLP-1 drugs this newsletter has covered extensively — and the combination trial data is further along than most research-compound coverage suggests.

It's a different molecule from retatrutide with a similar dual-pathway logic. The trial data is earlier-stage, and the research-compound version is further removed from it.

It's a real protein with a genuinely striking name origin and an active aging-research program behind it. The compound sold under that name is a much smaller piece of that story.

It has a genuine, decades-old physiological research base. The mold-illness and chronic-fatigue claims attached to it in community use are a more recent, more contested addition.

It comes from the same Russian gerontology research program we examined in our epitalon coverage, aimed at the thymus gland instead of the pineal gland. The evidence profile has a familiar shape.

Community anecdotes about a bad reaction circulate constantly. What it would actually take to turn one into a usable safety signal is a much higher bar.

It's marketed as a next-generation cognitive peptide. We went looking for the human research behind that positioning and came back with very little.

It's been an approved stroke and dementia treatment in several countries for decades. Its current research-compound buyers are mostly after something else entirely.

It has a real, specific clinical development history — for one narrow condition. That's not the story told in most listings selling it as a general gut-health compound.

It's often mentioned in the same breath as MOTS-c as a mitochondrial-derived peptide. The two have different discovery histories and different gaps in their evidence.

It's designed to isolate one effect of a well-known hormone while leaving out the effect that makes that hormone risky to use casually.

It's an FDA-approved drug for labor and delivery. Almost none of its research-compound use has anything to do with that approval.

A COA's purity number is a summary. The underlying mass spectrometry data behind it is where the actual evidence lives — and almost nobody asks to see it.

A single vial combining several named compounds sounds efficient. It also makes independent verification of what's inside substantially harder.

It's one of the most potent growth hormone secretagogues studied — and one with a genuinely separate research thread on heart tissue that gets less attention than its growth-hormone effects.

Community-maintained vendor lists carry real weight with buyers. We looked into how a seller actually earns a spot on one — and how easy that process is to game.

It's not a peptide at all — it's a small-molecule enzyme inhibitor. The distinction matters more than most listings let on.

Unlike most compounds in this newsletter, MOTS-c is encoded in the human genome and produced naturally. That doesn't mean supplementing more of it does what the marketing claims.

Blocking myostatin sounds like a straightforward path to more muscle. The actual research on this specific compound is thinner than the claim.

It plays a genuinely important role in triggering the hormonal cascade behind puberty and fertility. That's not the same as having evidence for the uses it's marketed for.

BPC-157 is now sold in capsules as often as vials. The oral bioavailability question that raises rarely gets addressed in the listing.

A COA from six months ago tells you about a batch that may no longer be the one in the vial. How often a seller should retest is a real question with a real answer.

Before CJC-1295 and ipamorelin became the community standard pairing, these two compounds were the standard. They're still sold — with a notably different side-effect profile.

Two names, one mechanism, and a marketing history that has confused most of the buyers who take it. What the receptor science actually says.

Unlike most of what this newsletter covers, thymosin alpha-1 has been an approved medication in dozens of countries for decades. That doesn't settle every question buyers have about it.

It's sold today as a research compound for fat metabolism. What's less frequently mentioned is that it was already tested, at scale, in a Phase 2b trial — and missed its primary endpoint.

The longevity claims around epitalon trace back to a specific body of Russian gerontology research. Reading that research directly tells a narrower story than the compound's current reputation.

A COA's endotoxin line item is one of the fields buyers skip past fastest — and one of the ones that matters most for anything injected.

It's on nearly every product this newsletter covers. Almost nobody using those products is doing the research the label describes.

It started as a topical anti-wrinkle ingredient studied by cosmetics companies. Its evidence base still mostly lives there — not in the injectable research-compound listings now selling it.

MT-2 has one of the more unusual origin stories in this category — a university research program that was actually trying to develop it as an approved drug, before it wasn’t.

Every compound we cover has some evidence gap. DSIP’s is unusually wide — and unusually old.

Almost everything in this space is sold as a research compound. Tesamorelin is different: it’s an approved medication with a published Phase 3 trial record. That makes it a useful benchmark for what real evidence looks like.

GHK-Cu has one of the longest research histories of any compound in this newsletter’s coverage — discovered in 1973, and still being actively studied today.

We sent identical split samples from four commercial peptide batches to three accredited third-party labs. The purity figures that came back weren’t identical — and the reasons why say more about the state of the industry than any single number could.

The five fields worth checking before the purity number — and what each one is actually telling you.

How retatrutide’s three-receptor mechanism differs from the first wave of GLP-1 compounds, in plain terms.

We asked a working microbiology lab technician to walk us through what happens between “sample received” and a final sterility result — and why that gap is longer than most buyers expect.

A close read of the preclinical literature behind one of the most talked-about peptides in the community — and an honest accounting of the gap between animal models and everything else.

Three compound generations, three different receptor strategies. A plain-terms map of what separates them.

Two compounds, two different mechanisms, one shared target. The pharmacology behind the industry’s most common pairing.

The cellular biology behind NAD+ is genuinely well-established. The leap from there to anti-aging claims is doing more work than most marketing admits.

A three-amino-acid fragment with an outsized research footprint. What KPV is, and what the inflammation research actually says.

Our most-read story of last year explains the origin of this publication’s entire testing methodology — and why we stopped taking certificates at face value.

Two Russian-developed peptides with decades of domestic clinical use and a much thinner footprint in Western research literature.